High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of patients with a significant unmet need. The estimated probability of disease recurrence or death within 4 years of diagnosis is 50% and the prognosis is very grave for those who experience a recurrence. The purpose of the study is to compare the disease free survival (DFS) of ADXS11-001 to placebo administered following CCRT with curative intent in subjects with HRLACC.
SponsorsThis trial is sponsored by Advaxis Immunotherapies.
Interested in Clinical Trial?
Providers Associated With This Trial
- Jennifer M. Scalici, M.D.Gynecologic OncologistAssociate Professor of Interdisciplinary Clinical Oncology
- Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Chief of Gynecologic Oncology Service; Associate Director for Clinical Research, Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology